



Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India.
Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: info@nglfinechem.com CIN L24110MH1981PLC025884, Website www.nglfinechem.com

May 21, 2026

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400 001.

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No.C/1, G
Block, Bandra Kurla Complex, Bandra East,
Mumbai 400050.

Scrip Code: 524774

Symbol: NGLFINE

Sub: Outcome of the Board Meeting Dated May 21, 2026

Dear Sir/Madam,

We wish to inform you that, the Board of Directors of the Company at their meeting held today i.e. on Thursday, May 21, 2026 at 301 E-Square, Subhash Road, Vile Parle East, Mumbai 400057 inter-alia considered and approved the following:

1. Audited Financial Results (Standalone & Consolidated) along with Statutory Auditor's Report for the quarter and year ended on March 31, 2026 pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015;
2. Statement of Assets & Liabilities (Standalone & Consolidated) as on March 31, 2026;
3. Recommendation of final Dividend of Rs.1.75/- per fully paid up equity share of Rs.5/- each for the financial year ended on March 31, 2026;
4. The 45th Annual General Meeting (AGM) will be held on Tuesday, August 25, 2026, through Video Conferencing (VC) or Other Audio Visual Means (OAVM);
6. The Record date for the purpose of the Annual General Meeting and payment of final dividend is Tuesday, August 18, 2026;
7. The Register of Members and Share transfer books will remain closed from Wednesday, August 19, 2026 to Tuesday August 25, 2026 (both days inclusive);
8. Appointment of Mr. Hemant Shetye, Designated Partner HSPN & Associates LLP, as Scrutinizer for 45th Annual General Meeting of the Company;
10. Approved the appointment of M/s. KD Practice Consulting Pvt. Ltd. as Internal Auditors of the Company for the financial year 2026-27;
11. Approved the appointment of M/s. Sanghavi Randeria & Associates, as Cost Auditor of the Company for the financial year 2026-27;
12. Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved reappointment of Re-Appointment of Mr. Rajesh Lawande (DIN: 00327301) as Whole-Time Director of the Company for the Company for a term of consecutive five (5) years with effect from June 1, 2026, subject to approval of shareholders at the ensuing AGM.;



Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India.
Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: info@nglfinechem.com CIN L24110MH1981PLC025884, Website www.nglfinechem.com

13. Re-appointment of Mrs. Sarala Menon (DIN: 09433901) as an Independent Director of the Company for the Company for a term of consecutive five (5) years with effect from December 14, 2026, subject to approval of shareholders at the ensuing AGM.;

The relevant details as per the requirements of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as Annexure A, B, C and D.

The meeting of the Board of Directors commenced at 6.30 p.m. and concluded at 8.45 p.m.

You are requested to kindly take the information on record.

Thanking you,

Yours faithfully,

For NGL Fine-Chem Limited

Shivam Gharat
Company Secretary & Compliance Officer
Membership No: A56704

Encl: As above.



MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

102, 1st Floor, 47 Avenue, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Offi. # 2618 5110

3158 5697

shailesh.manek@gmail.com

shailesh@camanek.com

www.camanek.com

SHAILESH MANEK

B.Com. (Hons), Grad. C.W.A., F.C.A.

Cell : +91 93222 26311

MITTUL B. DALAL

B.Com. F.C.A.

Cell : +91 80973 74277

Independent Auditor's Report on Audit of the Consolidated Financial Results of M/s. NGL Fine-Chem Limited ("the Company") pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

TO THE BOARD OF DIRECTORS OF M/S.NGL FINE-CHEM LIMITED

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of M/s.NGL FINE - CHEM LIMITED (the "Company") and its wholly owned subsidiary (the Company and its wholly owned subsidiary together referred to as the "Group"), for the three months and year ended 31st March, 2026 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- (i) includes the results of its wholly owned subsidiary M/s.Macrotech Polychem Pvt. Ltd;
- (ii) is presented in accordance with the requirements of Regulation 33 and 52 of the Listing Regulations; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the quarter and year ended 31st March, 2026.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended 31st March, 2026

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results for the year ended 31st March, 2026, section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the quarter and year ended 31st March, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

MANEK & ASSOCIATES

Management's Responsibilities for the Consolidated Financial Results for the year ended 31st March, 2026

This Statement which includes Consolidated financial results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Statement has been compiled from the related audited interim condensed consolidated financial statements for the three months and year ended 31st March, 2026. This responsibility includes preparation and presentation of the Consolidated Financial Results for the quarter and year ended 31st March, 2026 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Ind AS, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Company, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Boards of Directors either intend to liquidate their respective entities or to cease operations, or have no realistic alternative but to do so.

The respective Boards of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results for the year ended 31st March, 2026.

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the quarter and the year ended 31st March, 2026 as a whole, are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

MANEK & ASSOCIATES

- Identify and assess the risks of material misstatement of the Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the Holding Company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 and 52 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Results, including the disclosures, and whether the Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Consolidated Financial Results of which we are the independent auditors.

Materiality is the magnitude of misstatements in the Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Results.

MANEK & ASSOCIATES

We communicate with those charged with governance of the Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal financial control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended 31st March, 2026 being the balancing figures between the audited figures in respect of the full financial year ended 31st March, 2026 and the published unaudited year-to-date figures up to the end of the third quarter of the current financial year, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", which were subjected to a limited review by us, as required under the Listing Regulations. Our opinion is not modified in respect of the above matters

For MANEK AND ASSOCIATES
Chartered Accountants
Firm's registration number: 0126679W



M B Dalal

(Mittul B Dalal)
Partner

Membership number: 172676
UDIN: 26172676TNERIJ8912

Mumbai
Dated: 21st May, 2026.



MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

102, 1st Floor, 47 Avenue, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Offi. # 2618 5110
3158 5697
shailesh.manek@gmail.com
shailesh@camanek.com
www.camanek.com

SHAILESH MANEK

B.Com. (Hons), Grad. C.W.A., F.C.A.

Cell : +91 93222 26311

MITTUL B. DALAL

B.Com. F.C.A.

Cell : +91 80973 74277

Independent Auditor's Report on Audit of the Standalone Financial Results of M/S. NGL Fine-Chem Limited ("the Company") pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

TO THE BOARD OF DIRECTORS OF M/S.NGL FINE-CHEM LIMITED

Opinion

We have audited the accompanying Statement of Standalone Financial Results of **M/s. NGL FINE-CHEM LIMITED** (the "Company"), for the three months and year ended 31st March, 2026 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- a. is presented in accordance with the requirements of Regulation 33 and 52 of the Listing Regulations; and
- b. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the quarter and the year then ended 31st March, 2026.

Basis for Opinion on the Audited Standalone Financial Results for the year ended 31st March, 2026

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results for the year ended 31st March, 2026, section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the quarter and year ended 31st March, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

MANEK & ASSOCIATES

Management's Responsibilities for the Standalone Financial Results for the year ended 31st March, 2026

This Statement, which includes the Standalone financial results is the responsibility of the Company's Board of Directors, and has been approved by them for the issuance. The Statement has been compiled from the related audited Interim condensed standalone financial statements for the three months and year ended 31st March, 2026. This responsibility includes preparation and presentation of the Standalone Financial Results for the quarter and year ended 31st March, 2026 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind AS, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Standalone Financial Results by the Directors of the Company, as aforesaid.

In preparing the Standalone Financial Results, the respective Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results for the year ended 31st March, 2026.

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the quarter and the year ended 31st March, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

MANEK & ASSOCIATES

- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 and 52 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results of the Company to express an opinion on the Standalone Financial Results.

Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal financial control that we identify during our audit.

MANEK & ASSOCIATES

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended 31st March, 2026 being the balancing figures between the audited figures in respect of the full financial year ended 31st March, 2026 and the published unaudited year-to-date figures up to the end of the third quarter of the current financial year, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", which were subjected to a limited review by us, as required under the Listing Regulations. Our opinion is not modified in respect of the above matters.

For MANEK AND ASSOCIATES
Chartered Accountants
Firm's registration number: 0126679W



M B Dalal

(Mittul B Dalal)
Partner

Membership number: 172676
UDIN: 26172676SRIFAT6104

Mumbai

Dated: 21st May, 2026.

NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road, Vile Parle East, Mumbai 400057, Maharashtra, India

CIN: L24110MH1981PLC025884



AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

Part I: Statement of Consolidated and Standalone Audited Results for the Quarter and Year ended 31st March 2026

Rupees in lakhs

	Particulars	Consolidated					Standalone				
		Quarter Ended		Year Ended			Quarter Ended		Year Ended		
		31.03.2026 (Audited)	31.12.2025 (Unaudited)	31.03.2025 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)	31.03.2026 (Audited)	31.12.2025 (Unaudited)	31.03.2025 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)
I	Revenue from Operations	14,923.28	12,750.99	9,497.14	50,095.47	36,825.67	14,474.55	12,633.09	9,301.75	48,877.38	35,929.35
II	Other Income	245.92	461.15	(96.56)	1,472.82	863.04	251.18	468.85	(79.02)	1,485.24	975.84
III	Total Revenue (I+II)	15,169.20	13,212.14	9,400.58	51,568.29	37,688.70	14,725.73	13,101.94	9,222.73	50,362.62	36,905.19
IV	Expences :										
	a) Cost of Material Consumed	6,729.93	6,270.50	5,118.16	24,721.78	18,241.25	6,806.64	6,398.82	5,178.02	24,963.49	18,379.74
	b) (Increase)/Decrease in stock in trade and work in progress	360.10	(319.38)	(337.93)	(772.72)	(0.59)	284.01	(247.75)	(285.95)	(839.03)	135.66
	c) Employee benefits expenses	1,695.98	1,708.46	1,424.74	6,550.08	5,554.61	1,569.44	1,572.46	1,294.27	6,025.46	5,071.37
	d) Finance Costs	100.76	107.47	97.36	446.75	233.41	99.48	105.60	94.69	440.16	230.74
	e) Depreciation and amortisation expenses	505.14	518.08	332.04	1,958.31	1,245.11	423.54	434.96	253.19	1,629.60	926.95
	f) Other expenses	3,996.04	2,860.04	2,660.19	12,327.32	9,643.49	4,055.09	2,900.45	2,724.54	12,680.89	9,772.50
	Total Expenses (IV)	13,387.95	11,145.16	9,294.57	45,231.52	34,917.28	13,258.20	11,164.54	9,258.76	44,900.57	34,516.96
V	Profit/(loss) before exceptional items and tax (III-IV)	1,781.25	2,066.99	106.02	6,336.77	2,771.42	1,467.53	1,937.40	(36.03)	5,462.05	2,388.23
VI	Exceptional Items	-	-	-	-	-	-	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	1,781.25	2,066.99	106.02	6,336.77	2,771.42	1,467.53	1,937.40	(36.03)	5,462.05	2,388.23
VIII	Tax Expense										
	a) Current Tax	(690.00)	(468.00)	(35.50)	(1,688.00)	(650.50)	(610.00)	(430.00)	-	(1,450.00)	(560.00)
	b) Prior Years	82.68	-	25.42	81.80	27.80	85.27	-	25.60	84.38	25.60
	c) Deferred Tax	174.63	(29.92)	(41.57)	82.10	(36.30)	172.63	(33.78)	(41.62)	66.79	(40.63)
IX	Profit/(Loss) for the period from continuing operations (VII-VIII)	1,348.56	1,569.07	54.36	4,812.67	2,112.43	1,135.42	1,473.62	(52.06)	4,163.22	1,813.20
X	Other Comprehensive Income										
	a. Gain/(Loss) on actuarial valuation of post employment benefits	(12.46)	(5.63)	(1.52)	(32.38)	(32.13)	(9.88)	(5.87)	(1.70)	(30.47)	(32.48)
	b. Deferred tax on above	3.14	1.42	0.38	8.15	8.09	2.49	1.48	0.43	7.67	8.17
	c. Other Comprehensive Income (Net of Tax)	(9.33)	(4.22)	(1.14)	(24.23)	(24.04)	(7.39)	(4.39)	(1.27)	(22.80)	(24.30)
XI	Total Comprehensive Income	1,339.23	1,564.85	53.22	4,788.44	2,088.39	1,128.03	1,469.23	(53.33)	4,140.42	1,788.90
XII	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90	308.90
XXIII	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A	32,614.89	27,934.57	N.A	N.A	N.A	31,684.77	27,652.44
XIV	Earnings Per Share (EPS)										
	a) Basic	21.83	25.40	0.88	77.90	34.19	18.38	23.85	(0.84)	67.39	29.35
	b) Diluted	21.83	25.40	0.88	77.90	34.19	18.38	23.85	(0.84)	67.39	29.35



NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road, Vile Parle East, Mumbai 400057, Maharashtra, India

CIN: L24110MH1981PLC025884



AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

Part II: Statement of Consolidated and Standalone Assets and Liabilities as on 31st March 2026

Rupees in lakhs

PARTICULARS	Consolidated Statement of Assets & Liabilities		Standalone Statement of Assets & Liabilities	
	As at 31.03.2026	As at 31.03.2025	As at 31.03.2026	As at 31.03.2025
	AUDITED	AUDITED	AUDITED	AUDITED
ASSETS				
(1) Non-current assets				
(a) Property, plant and equipment	16,380.44	14,174.17	14,367.75	11,911.38
(b) Intangible assets	28.23	39.73	28.19	39.56
(c) Capital work-in-progress	9,456.72	4,972.58	9,456.72	4,972.58
(d) Goodwill	15.27	15.27		
(e) Right of Use Assets	7.39	37.96	7.39	37.96
(f) Financial assets				
(i) Non-Current Investments	-	-	372.51	372.51
(ii) Non-Current Loans	52.37	55.15	1,317.19	1,780.72
(iii) Other Non-Current Financial Assets	932.96	621.89	882.29	574.83
(g) Non-Current Tax Assets (Net)	31.61	142.16	-	109.56
(h) Other Non-Current Assets	5.77	21.30	5.77	21.29
(2) Current assets				
(a) Inventories	7,027.96	5,127.01	6,762.58	4,906.74
(b) Financial assets				
(i) Current Investments	3,918.83	5,966.34	3,918.83	5,966.34
(ii) Trade Receivables	13,087.52	8,284.25	12,547.00	7,977.42
(iii) Cash and Cash Equivalents	280.81	53.45	54.94	52.36
(iv) Bank balances other than (iii) above	230.21	443.80	219.78	433.73
(v) Other Current Financial Assets	172.43	350.83	153.48	346.48
(c) Other Current Assets	2,921.06	3,162.48	2,868.50	3,073.01
Total Assets	54,549.58	43,468.37	52,962.90	42,576.27
EQUITY AND LIABILITIES				
1. Equity				
(1) Equity				
(a) Equity share capital	308.90	308.90	308.90	308.90
(b) Other equity	32,614.05	27,934.57	31,684.77	27,652.44
2. Liabilities				
(I) Non-Current Liabilities				
(a) Financial Liabilities				
(i) Non-Current Borrowings	5,640.33	2,533.56	5,640.33	2,533.56
(ii) Lease Liabilities	-	38.71	-	38.71
(iii) Other Non-Current Financial Liabilities	337.83	145.27	313.14	125.58
(b) Non-Current Provisions	465.91	400.13	440.14	380.54
(c) Deferred Tax Liabilities (Net)	157.37	247.62	148.35	222.82
(d) Other Non-Current Liabilities	23.80	17.36	23.80	17.35



NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road, Vile Parle East, Mumbai 400057, Maharashtra, India

CIN: L24110MH1981PLC025884



AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

Part II: Statement of Consolidated and Standalone Assets and Liabilities as on 31st March 2026

Rupees in lakhs

PARTICULARS	Consolidated Statement of Assets & Liabilities		Standalone Statement of Assets & Liabilities	
	As at 31.03.2026	As at 31.03.2025	As at 31.03.2026	As at 31.03.2025
	AUDITED	AUDITED	AUDITED	AUDITED
(II) Current Liabilities				
(a) Financial Liabilities				
(i) Current Borrowings	5,202.25	4,799.60	5,112.39	4,684.33
(ii) Lease Liabilities	7.95	-	7.95	-
(iii) Trade Payables	6,460.94	5,208.95	5,987.51	4,823.53
(iv) Other Current Financial Liabilities	2,868.12	1,138.81	2,864.26	1,108.06
(b) Other Current Liabilities	168.25	603.79	161.58	593.00
(c) Current Provisions	102.12	91.09	98.03	87.44
(d) Current Tax Liabilities (Net)	191.76	-	191.76	-
Total Equity and Liabilities	54,549.58	43,468.37	52,962.90	42,576.27

Part III: Consolidated and Standalone Cash Flow Statement for the year ended 31st March 2026

Rupees in lakhs

Particulars	Consolidated Cash Flow		Standalone Cash Flow	
	For the year ended March 31, 2026	For the year ended March 31, 2025	For the year ended March 31, 2026	For the year ended March 31, 2025
A. Cash flow from operating activities				
Profit before tax	6,335.93	2,771.43	5,462.06	2,388.25
Adjustments for:				
Depreciation, Amortisation & Impairment Expense	1,958.31	1,245.10	1,629.60	926.95
Unrealised Loss / (Gain) on Non-Current Investment	273.25	(59.51)	273.25	(59.51)
Finance costs	446.75	234.44	440.16	230.74
Dividend income	(1.27)	(23.18)	(1.27)	(23.18)
Interest on Deposit with Banks and Others	(67.66)	(59.81)	(126.48)	(180.36)
Other Comprehensive Income	(24.23)	(24.04)	(22.80)	(24.30)
Operating Profit before Working Capital Changes sub total	8,921.08	4,084.44	7,654.51	3,258.59
Changes in working capital:				
(Increase) / Decrease in Inventories	(1,900.95)	(796.67)	(1,855.83)	(646.63)
(Increase) / Decrease in Trade receivables	(4,803.28)	677.55	(4,569.58)	335.95
(Increase) / Decrease in Other Current Financial Assets	391.99	(402.46)	406.95	(602.92)
(Increase) / Decrease in Other Current Assets	241.42	(1,335.00)	204.51	(1,078.66)
(Increase) / Decrease in Other Non-Current Loans	2.78	(36.25)	2.34	-
(Increase) / Decrease in Other Non-Current Assets	110.54	(142.16)	109.56	(179.39)
sub total	(5,957.49)	(2,034.99)	(5,702.05)	(2,171.66)



NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road, Vile Parle East, Mumbai 400057, Maharashtra, India

CIN: L24110MH1981PLC025884



AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

Part III: Consolidated and Standalone Cash Flow Statement for the year ended 31st March 2026

Rupees in lakhs

Particulars	Consolidated Cash Flow		Standalone Cash Flow	
	For the year ended March 31, 2026	For the year ended March 31, 2025	For the year ended March 31, 2026	For the year ended March 31, 2025
Increase / (Decrease) in Trade payables	1,251.99	270.31	1,143.98	695.52
Increase / (Decrease) in Other Current Financial Liabilities	1,737.26	726.05	1,764.15	817.96
Increase / (Decrease) in Other Non-Current Financial Liabilities	153.84	183.98	148.85	-
Increase / (Decrease) in Other Current Provisions	11.03	25.58	10.59	66.13
Increase / (Decrease) in Other Current Liabilities	(243.79)	531.74	(239.66)	-
Increase / (Decrease) in Other Non-Current Liabilities	(83.81)	30.33	(68.01)	34.57
Increase / (Decrease) in Other Non-Current Provisions	65.80	77.58	59.60	72.81
sub total	2,892.32	1,845.58	2,819.49	1,686.99
Cash generated from operations	5,855.92	3,895.03	4,771.95	2,773.92
Net income tax paid	(1,524.10)	(659.00)	(1,298.82)	(575.03)
Net Cash Flow generated from / (used in) Operating Activities (A)	4,331.82	3,236.03	3,473.13	2,198.90
B. Cash flow from investing activities				
Payment for Acquisition of Property, Plant and Equipment (including Capital Work in Progress) & Other Intangible Assets	(8,985.01)	(7,428.55)	(8,906.53)	(7,376.38)
Proceeds from Sale of Property, Plant and Equipment / Intangible Assets	378.36	52.60	378.36	52.60
Unrealised Loss / (Gain) on Non-Current Investment	(273.25)	59.51	(273.25)	59.51
Dividend Income	1.27	23.18	1.27	23.18
Interest on Deposit with Banks and Others	67.66	59.81	126.48	180.36
Net Proceeds from Sale of Investments	2,047.51	(606.93)	2,047.51	(606.95)
Loan repaid by / (given to) Subsidiary	-	-	515.00	1,212.00
Interest on Loan from Subsidiary (Net of TDS)	-	-	(53.81)	(113.24)
Change in Bank Balance not considered as Cash & Cash Equivalents	(311.07)	597.21	(307.66)	776.89
Other Non-Current Assets	15.53	274.72	15.52	(27.99)
Net Cash Flow generated from / (used in) Investing Activities (B)	(7,059.00)	(6,968.45)	(6,457.10)	(5,820.02)
C. Cash flow from financing activities				
Dividend Paid	(108.12)	(108.12)	(108.12)	(108.12)
Proceeds from / (Repayment of) Non-Current Borrowing	3,106.77	2,459.08	3,106.77	2,459.08
Proceeds from / (Repayment of) Current Borrowing	402.65	1,629.84	428.06	1,514.57
Finance Costs Paid	(446.75)	(234.44)	(440.16)	(230.74)
Net Cash Flow generated from / (used in) Financing Activities (C)	2,954.55	3,746.37	2,986.55	3,634.80
Net increase/ (decrease) in Cash and cash equivalents (A+B+C)	227.36	13.93	2.57	13.68
Add: Cash and cash equivalents at the beginning of the year	53.45	39.52	52.36	38.68
Cash and Cash Equivalents at the end of the year (refer Note *)	280.81	53.45	54.93	52.36
Cash and cash equivalents at the end of the year				
Comprises of:				
(a) Cash on hand	15.69	18.38	15.14	17.82
(b) Balances with banks				
(i) In current accounts	265.12	35.07	39.79	34.54
	280.81	53.45	54.93	52.36



NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road, Vile Parle East, Mumbai 400057, Maharashtra, India

CIN: L24110MH1981PLC025884



AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

Notes:

- 1 The above audited standalone and consolidated results for the quarter and year ended March 31, 2025 were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Thursday, 21st May, 2026.
- 2 These statements have been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015 and Companies (Indian Accounting Standard) (Amendment) Rules 2016.
- 3 The financial results for the year ended March 31, 2026 have been audited by the statutory auditors of the company. The audit report does not contain any qualifications.
- 4 The Board of Directors have recommended a dividend of Rs. 1.75 per fully paid up equity share of Rs. 5 each aggregating to Rs.108.12 lakhs for the Financial Year 2025-26 which is based on relevant share capital as on 31-03-2026.
- 5 In accordance with Ind AS 108 - Operating Segments, the Group has only one reportable primary business segment - namely Pharmaceuticals. However the Group has a secondary geographical segment which is disclosed in consolidated financial statements as per Ind AS 108. Information regarding the geographical distribution of revenue is given below.

(Rupees in lakhs)

	2025-26	2024-25
India	15,790.03	9,387.33
Europe	68.73	4,393.59
Asia Pacific	14,445.00	11,285.32
USA	15.02	478.75
Rest of the world	19,094.49	10,757.93
Total	49,413.27	36,302.92

- 6 Previous period figures have been regrouped/rearranged wherever necessary.

Place: Mumbai
Date: 21-May-2026



For and On behalf of Board of Directors

Rahul Nachane
Managing Director



NGL Fine-Chem Limited

Regd. Office: 301, E-Square, Subhash Road, Vile Parle East, Mumbai-400057, Maharashtra, India
Tel.: 022-40842222, Email: info@nglfinechem.com, CIN: L24110MH1981PLC025884, Website: www.nglfinchem.com

May 21, 2026

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400 001.

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No.C/1, G
Block, Bandra Kurla Complex, Bandra East,
Mumbai 400050.

Scrip Code: 524774

Symbol: NGLFINE

Sub: Declaration regarding Audit Report with Unmodified Opinion under Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

Pursuant to the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by SEBI Notification No. SEBI/LAD-NRO/GN/2016-14/001 dated May 25, 2016, and SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016, we hereby declare that the Statutory Auditors of the Company, M/s. Manek & Associates, Chartered Accountants (Firm Registration No. 126679W), have issued the Audit Report with Unmodified Opinion on the Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and financial year ended March 31, 2026.

You are requested to kindly take the information on record.

Thanking you,

**Yours faithfully,
For NGL Fine-Chem Limited**



**Rahul Nachane
Managing Director
DIN: 00223346**

Encl: As above.



Annexure A

Name	KD Practice Consulting Pvt. Ltd.
Reason for Change	Appointed by Board in its meeting held on May 21, 2026 Term: For the Financial Year 2026-27
Date and term of Appointment/Re-appointment	Appointed by Board in its meeting held on May 21, 2026 Term: For the Financial Year 2026-27
Brief Profile	KD Practice Consulting is one of the renowned internal audit firm specializing in helping its clients by conducting internal audits, identifying process gaps and strengthening internal controls. They work with the management to create strong internal control environment and help in better corporate governance.
Disclosure of relationship between Directors (in case of appointment of a Director)	Not Applicable.

Annexure B

Name	Sanghavi Randeria & Associates
Reason for Change	Appointment of Cost Auditor Term: For the Financial Year 2025-26
Date and term of Appointment/Re-appointment	Appointed by Board in its meeting held on May 21, 2026 Term: For the Financial Year 2026-27
Brief Profile	Sanghavi Randeria & Associates is a firm of professional Cost Accountants established in the year 2007. The firm has rich experience in core field viz. establishing Costing System, Cost Audit, Maintenance of Cost records, Compliance Certificate, Internal Audit and GST Audit etc. The firm also provides the expertise value added services in whole gamut of Indirect Taxation which includes Custom and GST. We provide services related to ROC matters viz. E-filing of Registrar of Companies return, formation of Companies, issue Digital Signature Certificate (DSC). We provide consultancy in Export Import area and Export incentives as per Foreign Trade policy. We are catering to Pharmaceuticals, Chemicals, Engineering and Textiles, paper, FMCG & Service Industries.
Disclosure of relationship between Directors (in case of appointment of a Director)	Not Applicable.

Annexure C

Particulars	Details
Reason for change viz. appointment, Resignation, removal, death or otherwise	Re-Appointment
Date of appointment and terms of appointment	Board in its meeting held on May 21, 2026 has appointed Mr. Rajesh Lawande as Whole-Time Director of the Company for first term of 5 (five) consecutive years commencing from June 1, 2026, subject to approval of shareholders of the Company to be obtained within three months hereof.
Brief Profile	Mr. Rajesh Lawande, aged 50 years having over 20 years of experience in Pharmaceutical sector. He is M.Sc. (Chemistry) from IIT Mumbai and PGDBA from IIM Lucknow. 2 decades of experience in the overall operations of Company. He is responsible to procure the inputs for the company. He is also responsible for structural development of the company and R & D department. Under his leadership, Company has made a strong presence in the Pharmaceutical Sector today.
Disclosure of relationship between Directors (in case of appointment of a Director)	Mr. Rajesh Lawande is related to Mrs. Ajita Nachane (Sister).
Affirmation that Director is not debarred from holding the office of Director by virtue of any SEBI order or authority	Mr. Rajesh Lawande is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Annexure D

Particulars	Details
Reason for change viz. appointment, Resignation, removal, death or otherwise	Re-Appointment
Date of appointment and terms of appointment	Board in its meeting held on May 21, 2026 has appointed Mrs. Sarala Menon as Managing Director of the Company for first term of 5 (five) consecutive years commencing from December 14, 2026, subject to approval of shareholders of the Company to be obtained within three months hereof.
Brief Profile	Mrs. Sarala Menon, having over 35 years of experience in Manufacturing and Supply Chain roles, with the main area of interest being industrial operations and management. she has Chemical Engineering Degree from the National Institute of Technology in Warangal, and an MBA from the NMIMS in Mumbai. Her strategic leadership and deep industry expertise were instrumental in driving operational excellence and nurturing a culture of continuous improvement. Her leadership in quality, safety, and customer service is a key asset to the Company.
Disclosure of relationship between Directors (in case of appointment of a Director)	Mrs. Sarala Menon is not related to any other Director of the Company.
Affirmation that Director is not debarred from holding the office of Director by virtue of any SEBI order or authority	Mrs. Sarala Menon is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.